Outside Consultant Will Evaluate FDA's Postmarketing Studies Practices

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 6
Volume 15
Issue 6

The FDA has awarded a $1.09 million contract for an evaluation of the agency's process of establishing postmarketing, or phase IV, studies. The consulting firm of Booz Allen Hamilton will conduct the 1-year evaluation and make recommendations to the agency for improving and standardizing the process.

ROCKVILLE, Maryland—The FDA has awarded a $1.09 million contract for an evaluation of the agency's process of establishing postmarketing, or phase IV, studies. The consulting firm of Booz Allen Hamilton will conduct the 1-year evaluation and make recommendations to the agency for improving and standardizing the process.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content